DOSSIER · 13F-HR · Q1 2026

Virtus Investment Advisers, LLC

$363M in tracked AUM across 450 positions as of Q1 2026.

VI
CIK 0000019481 · last filed Mar 31, 2026
Total AUM
$363M
as of Q1 2026
Holdings
450
positions
Whale Score
43
43
tracked
Activity
no data
changes this Q
AI Analysis · Q1 2026

Position sizing, not stock picking, is the story at Virtus Investment Advisers: across a $362.5 million, 450-position Q1 2026 book, even the largest holding, Gilead Sciences, is just 0.79% of assets, and the top 50 names are all clustered tightly between roughly 0.51% and 0.79% — a maximally diversified structure where no individual stock can meaningfully move the portfolio's overall shape. That structure also means a large share of names crossing in or out of a "top 50 by value" cut quarter to quarter likely reflects small price moves shuffling rank order among similarly-sized positions, not a wholesale change in strategy. The book's handful of clean, unambiguous trades: Oxford Lane Capital, a CLO closed-end fund, was the only meaningfully increased position (+39.2% in shares, a real $574,634 addition), while Applied Materials was trimmed the hardest (-31.9% in shares, -$914,288) — modest single-digit-percent reductions in Ross Stores, WABTEC, Delta Air Lines, Walmart and Cisco round out the quarter's real activity. With a whaleScore of 43.00, this filer's structure — not any individual position — is the actual story.

A book with no room for concentration

The largest position, Gilead Sciences, sits at just 0.79% of assets. The next several dozen names — Amgen, Regeneron, Vertex Pharmaceuticals, Ross Stores, Berkshire Hathaway, Coca-Cola, Applied Materials and more — are all packed into a narrow band roughly between 0.51% and 0.79%. With 450 total holdings and this tight a distribution, no single stock's move can meaningfully shift the portfolio's reported value; the whaleScore of 43.00, on the low end of this batch, reflects exactly that lack of any outsized single-name bet.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
GILD
GILEAD SCIENCES INC
$3M20K0.8%
02
AMGN
AMGEN INC
$3M8K0.8%
03
REGN
REGENERON PHARMACEUTICALS
$3M4K0.8%
04
IBRX
IMMUNITYBIO INC
$3M358K0.8%
05
VRTX
VERTEX PHARMACEUTICALS INC
$3M6K0.7%
06
INCY
INCYTE CORP
$3M27K0.7%
07
VRT
VERTIV HOLDINGS CO
$3M10K0.7%
08
ALNY
ALNYLAM PHARMACEUTICALS INC
$2M7K0.7%
09
EIX
EDISON INTL
$2M33K0.7%
10
ROST
ROSS STORES INC
$2M10K0.6%

Filing history

2026Q1Mar 31
$363M 1.5%
450 positionsView →
2025Q4Dec 31
$368M 5.3%
461 positionsView →
2025Q3Sep 30
$349M 18.1%
440 positionsView →
2025Q2Jun 30
$296M 22.5%
439 positionsLocked
2025Q1Mar 31
$241M 89.2%
301 positionsLocked
2024Q4Dec 31
$128M 0.4%
360 positionsLocked
2024Q3Sep 30
$127M 7.5%
340 positionsLocked
2024Q2Jun 30
$118M 15.5%
335 positionsLocked
2024Q1Mar 31
$140M 4.8%
347 positionsLocked
2023Q4Dec 31
$134M 9.2%
346 positionsLocked
2023Q3Sep 30
$147M 0.2%
242 positionsLocked
2023Q2Jun 30
$147M 3.1%
259 positionsLocked
Showing 12 of 87